(Prostate Cancer) Is Rucaparib Effective?
Medical Supporter — إشعار معلوماتي
هذه المقالة ملخص لمعلومات طبية دولية وليست نصيحة طبية، ولا يمكن أن تحل محل تشخيص طبيبك المعالج أو خطة العلاج. المعلومات المعروضة مجمّعة من منشورات عامة وبيانات رسمية لكبرى المؤسسات الطبية اليابانية؛ وتختلف ملاءمة ونتائج أي علاج من مريض لآخر ويجب أن يقيّمها طبيب مؤهل لكل حالة على حدة.
- February 24, 2023
- Reading time: 1 minute
On February 16–18, 2023, Alan Haruo Bryce et al. from Mayo Clinic presented the efficacy and safety results of rucaparib monotherapy in metastatic castration-resistant prostate cancer (mCRPC) from the TRITON3 Phase 3 trial at ASCO GU 2023 in San Francisco, California.
Trial Design
TRITON3 was a multicenter, randomized, open-label Phase 3 trial that randomized mCRPC patients in a 2:1 ratio to:
- Rucaparib group: 600 mg
- Physician's choice group: Enzalutamide, abiraterone, or docetaxel
Primary endpoint: Progression-free survival (PFS). Secondary endpoints: Overall survival (OS), objective response rate (ORR), duration of response, and PSA progression index.
Efficacy Results
Primary endpoint — Median PFS in BRCA-mutated patients:
- Rucaparib: 11.2 months
- Docetaxel: 8.3 months
- Enzalutamide/Abiraterone: 4.5 months
Median PFS in overall population:
- Rucaparib: 10.2 months
- Docetaxel: 8.3 months
- Enzalutamide/Abiraterone: 4.5 months
Secondary endpoint — Median OS in BRCA-mutated patients:
- Rucaparib: 24.3 months
- Docetaxel: 18.9 months
- Enzalutamide/Abiraterone: 22.1 months
Median OS in overall population:
- Rucaparib: 23.6 months
- Docetaxel: 19.1 months
- Enzalutamide/Abiraterone: 22.1 months
Safety Profile
Most common adverse event — asthenia/fatigue:
- Rucaparib: 61.1% | Docetaxel: 67.6% | Enzalutamide/Abiraterone: 57.6%
Most common Grade 3+ adverse events:
- Rucaparib: Anemia 61.1%
- Docetaxel: Neutropenia 14.1%
- Enzalutamide/Abiraterone: Hypertension 10.2%
Conclusions
Based on the TRITON3 trial results, Alan Haruo Bryce et al. concluded that rucaparib monotherapy improved progression-free survival compared to physician's choice (enzalutamide, abiraterone, or docetaxel) in mCRPC patients, with a safety profile consistent with previously known data.
Source: https://meetings.asco.org/abstracts-presentations/216883
- Clinical trial drug
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
هل تفكر في تلقّي العلاج في اليابان؟ هل تحتاج إلى معلومات ومساعدة؟
نساعدك في تنظيم المعلومات اللازمة للسفر الطبي إلى اليابان، والتواصل مع المؤسسات الطبية اليابانية، وترتيب استشارة رأي ثانٍ.الاستشارة الأولى مجانية؛ سيساعدك المستشار على توضيح الخطوات التالية.
Figure 1
Figure 2
Figure 3
Figure 4